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ABSTRACT
Introduction: The reported number of new leprosy
patients has barely changed in recent years. Thus,
additional approaches or modifications to the current
standard of passive case detection are needed to
interrupt leprosy transmission. Large-scale clinical
trials with single dose rifampicin (SDR) given as post-
exposure prophylaxis (PEP) to contacts of newly
diagnosed patients with leprosy have shown a 50–60%
reduction of the risk of developing leprosy over the
following 2 years. To accelerate the uptake of this
evidence and introduction of PEP into national leprosy
programmes, data on the effectiveness, impact and
feasibility of contact tracing and PEP for leprosy are
required. The leprosy post-exposure prophylaxis
(LPEP) programme was designed to obtain those data.
Methods and analysis: The LPEP programme
evaluates feasibility, effectiveness and impact of PEP
with SDR in pilot areas situated in several leprosy
endemic countries: India, Indonesia, Myanmar, Nepal,
Sri Lanka and Tanzania. Complementary sites are
located in Brazil and Cambodia. From 2015 to 2018,
contact persons of patients with leprosy are traced,
screened for symptoms and assessed for eligibility to
receive SDR. The intervention is implemented by the
national leprosy programmes, tailored to local
conditions and capacities, and relying on available
human and material resources. It is coordinated on the
ground with the help of the in-country partners of the
International Federation of Anti-Leprosy Associations
(ILEP). A robust data collection and reporting system is
established in the pilot areas with regular monitoring
and quality control, contributing to the strengthening
of the national surveillance systems to become more
action-oriented.
Ethics and dissemination: Ethical approval has
been obtained from the relevant ethics committees in
the countries. Results and lessons learnt from the
LPEP programme will be published in peer-reviewed
journals and should provide important evidence and
guidance for national and global policymakers to
strengthen current leprosy elimination strategies.
INTRODUCTION
Over the past 30 years, the prevalence of
diagnosed leprosy cases has declined by 95%,
from 5.2 million in 1985 to <200 000 in
2015.1 2 This remarkable reduction has often
been cited as a major public health success.
Indeed, in 2000, the WHO’s goal to elimin-
ate leprosy as a public health problem,
deﬁned as a prevalence of <1 leprosy patient
per 10 000 population, was ofﬁcially
reached.3 This contributed to a sharp
decline in ofﬁcial interest for leprosy in most
endemic countries, and a signiﬁcant reduc-
tion in ﬁnancial support for national pro-
grammes that manifested itself in reduced
case ﬁnding and diagnosis efforts.4–7 The
reduction of the recorded prevalence can be
Strengths and limitations of this study
▪ Includes sites in six leprosy endemic countries
and is complemented by sites in two additional
countries to answer key questions of contact
tracing and single dose rifampicin post-exposure
prophylaxis (SDR PEP) feasibility and impact
across various health systems in Asia, Africa and
South America.
▪ Implementation and coordination by national
programmes will help to facilitate PEP integration
into national strategies and thus ensure
sustainability.
▪ Expert guidance and close monitoring ensures
quality data collection and analysis.
▪ Results may not be fully relevant for countries
with fundamentally different health systems and
low-endemic areas.
▪ Differing contact definitions limit the potential to
pool results, and a focus on household
members in some countries may reduce the
impact of SDR PEP.
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attributed to the widespread availability of free multi-
drug therapy (MDT), along with a shortening of the
standard treatment.8 The reported annual number of
new cases has plateaued at 200 000–250 000 globally in
the past decade; with 213 899 new diagnoses reported in
2015.1 2 This stagnation, and the fact that still about
10% of the new diagnoses occur in children, suggests
ongoing leprosy transmission,4 7 while the continuing
detection of patients with advanced disease indicates
serious diagnostic delays.7 As a result, alternative control
strategies are needed to interrupt transmission of
Mycobacterium leprae and accelerate case detection.
The main risk factor for leprosy is prolonged close
contact with an infectious patient.9 Early case detection
and prompt treatment with MDT are the cornerstones
of the WHO recommendations for leprosy control10 11
but solid evidence exists that post-exposure prophylaxis
(PEP) with single dose rifampicin (SDR) can reduce
the risk of contacts to develop leprosy by 50–60%
over the 2 years following SDR administration.12–15
Chemoprophylaxis has already been used in the 60s and
70s when weekly dapsone for 2–3 years was tested, an
approach that proved too cumbersome to become
widely implemented.16–21 Other trials used acedapsone
every 10 weeks for 7 months.22 23 A meta-analysis of the
dapsone studies showed their superiority over placebo
with an overall reduction of the leprosy new case detec-
tion rate (NCDR) of 40% in contacts,16 17 20 while the
NCDR reduction of acedapsone prophylaxis was
51%.13 22 23 In 1988, SDR chemoprophylaxis (25 mg/
kg) was ﬁrst studied in the Southern Marquesas Islands
in a non-controlled trial.24 25 A follow-up survey 10 years
later suggested a 70% effectiveness of chemoprophy-
laxis. However, over the same period a 50% reduction in
the NCDR was observed in the non-treated population
of French Polynesia. Therefore, the true effectiveness of
SDR may have been 35–40%.26 In the mid-1990s, chemo-
prophylaxis was introduced on different Paciﬁc islands
where the leprosy NCDR had remained very high.27
Over two cycles, with a 1-year interval, 70% of the popu-
lation was screened for leprosy and treated prophylactic-
ally. Healthy adults received rifampicin, oﬂoxacin and
minocycline (ROM), while children under 15 years
received SDR.28 In 1999, a substantial reduction in the
NCDR was observed.27 Recent data indicate that trans-
mission is ongoing.29 In 2000, a study using rifampicin
only was initiated on ﬁve highly endemic Indonesian
islands.14 The population was screened before the inter-
vention and subsequently once a year for 3 years; two
doses of rifampicin were administered to asymptomatic
inhabitants with a 3.5 months interval, either in a
‘blanket’ approach where SDR was given to the entire
population, or a ‘contact’ strategy in which SDR was only
given to eligible household and neighbour contacts of
patients with leprosy. The NCDR on the control island
was 39/10 000. After 3 years, the cumulative NCDR in
the blanket group was signiﬁcantly lower (about 3
times), whereas no difference was found between the
control group and the islands where SDR was given to
contacts only.14
The COLEP trial in Bangladesh was a single-centre,
double-blind, cluster-randomised, placebo-controlled
study designed to determine the effectiveness of SDR in
contacts and to identify the characteristics of contact
groups most at risk of developing clinical leprosy.30 The
overall risk reduction for contacts during the ﬁrst 2 years
after SDR administration was 57%. There was no further
risk reduction beyond the 2 years12 and thereafter.31 The
overall number needed to treat to prevent a single diag-
nosis of leprosy among contacts was 265 after 2 years
and 297 after 4 years.12 The protective effect of SDR was
highest in contact groups with the lowest a priori risk for
leprosy: non-blood-related contacts, contacts of index
patients with paucibacillary leprosy and social contacts.12
Importantly, childhood vaccination with Bacillus
Calmette-Guérin (BCG) also had a protective effect of
nearly 60%, and previously immunised contacts
appeared to beneﬁt from an 80% protective effect.32
Considering all available evidence, it appears that
chemoprophylaxis should target deﬁned contact groups,
but under certain conditions, mass administration may
be warranted. High NCDRs, difﬁcult geographical acces-
sibility, insufﬁcient availability healthcare services or a
high level of stigma are reasons to prefer mass adminis-
tration to targeted PEP.13 Two international expert meet-
ings hosted by the Novartis Foundation in 2013 and
2014 and including physicians, epidemiologists and
public health professionals, concluded that contact
tracing followed by PEP for asymptomatic contacts has
the potential to offer a degree of protection, across
diverse settings, comparable to that reported in con-
trolled trials.1 33
To accelerate the translation of the existing evidence
into policy and motivate endemic countries to introduce
chemoprophylaxis into their routine leprosy activities,
the LPEP programme was designed. It aims to demon-
strate the effectiveness and impact on case detection
rates of contact tracing and screening combined with
SDR PEP under routine programme conditions, across a
diversity of health systems, national leprosy programmes
and geographical characteristics, and to determine oper-
ational parameters.
OBJECTIVES
The LPEP programme aims to assess contact tracing and
administration of SDR PEP implemented by national
leprosy programmes with regard to:
1. Impact on the new case detection rate, measured
through strengthened surveillance and reporting
systems
2. Feasibility in diverse routine programme settings
The LPEP programme provides a comprehensive
package, including systematic contact tracing and screen-
ing for early case detection and PEP administration for
asymptomatic contacts (ﬁgure 1). In addition, the
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programme also promotes capacity building for front-
line leprosy workers to strengthen screening and diagno-
sis, and for surveillance system managers to improve
data collection and reporting.
METHODS AND ANALYSIS
Study coordination
A steering committee of leprosy experts, policymakers,
academic researchers, people affected by leprosy and
the project partners (International Federation of
Anti-Leprosy Associations (ILEP) members, national
leprosy programmes and the Novartis Foundation) over-
sees the programme, advises on strategic and oper-
ational matters, establishes the dissemination strategy
and reviews programme publications. The Novartis
Foundation provides the overall coordination of the
LPEP programme and ensures ﬁnancial support. LPEP
country protocol development, programme manage-
ment and implementation at national level are handled
by the national leprosy programmes supported by the
respective ILEP partners. The Swiss Tropical and Public
Health Institute (Swiss TPH) and the Erasmus
University’s Medical Center (Erasmus MC) support the
local programme protocol development, provide train-
ing and assist with the strengthening of surveillance
systems operated by the national programmes. They
further monitor adherence to protocol and data quality,
coordinate data analysis and facilitate the dissemination
of the study results. All in-country activities of the aca-
demic partners are closely coordinated with, and sup-
ported by, the respective ILEP partner and the national
programme (ﬁgure 2). An annual meeting facilitates
progress and review and exchange among the partners.
Study areas
Participation in the LPEP programme was open to coun-
tries meeting the following criteria: (1) subnational
administrative units (eg, districts) with a high NCDR,
relatively easy access and a functioning leprosy control
infrastructure, (2) capacity for routine contact tracing
and screening in the local leprosy programme, (3)
declared interest from the Ministry of Health and (4)
commitment and resources to continue contact tracing
and PEP after the conclusion of the LPEP programme.
When selecting the countries, diversity in terms of geog-
raphy and leprosy programme organisation was taken
into account. Table 1 presents key leprosy indicators at
baseline in the selected LPEP sites in India, Indonesia,
Myanmar, Nepal, Sri Lanka and Tanzania. Additional
pilot sites are located in Brazil and Cambodia.
Study design
In agreement with its objectives; the LPEP programme is
implemented under routine conditions rather than as a
clinical trial. A general study protocol was prepared and
served as the basis for the elaboration of national LPEP
protocols tailored to the realities of each country. Patients
with leprosy diagnosed <2 years prior to the start of the
ﬁeld work (retrospective index patients) and patients
diagnosed during the programme period (3 years pro-
spective index patients) are eligible for inclusion. These
Figure 1 Conceptual framework of the impact of the LPEP
programme on the transmission of Mycobacterium leprae.
LPEP, leprosy post-exposure prophylaxis; MDT, multidrug
therapy; SDR PEP, single dose rifampicin post-exposure
prophylaxis.
Figure 2 Governance structure of the LPEP programme. ALM, American Leprosy Mission; Erasmus MC, Erasmus Medical
Center; GLRA, German Leprosy and Tuberculosis Relief Association; ILEP, International Federation of Anti-Leprosy Associations;
LPEP, leprosy post-exposure prophylaxis; NLR, Netherlands Leprosy Relief; Swiss TPH, Swiss Tropical and Public Health
Institute.
Barth-Jaeggi T, et al. BMJ Open 2016;6:e013633. doi:10.1136/bmjopen-2016-013633 3
Open Access
group.bmj.com on November 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
index patients have to meet the following inclusion cri-
teria: (1) conﬁrmed leprosy diagnosis and being on MDT
treatment for at least 4 weeks, (2) residency in an LPEP
pilot area, (3) one or more contacts (as deﬁned by the
local deﬁnition of contacts, see table 2) and (4) willing-
ness to disclose their disease status to the targeted con-
tacts. All traced contacts are screened for signs of leprosy.
Exclusion criteria for SDR administration are: (1) refusal
to give informed consent, (2) age <2 or 6 years (country-
speciﬁc age ranges are applied, see table 2), (3) preg-
nancy (PEP can be given after delivery), (4) rifampicin
use in the past 2 years (eg, for tuberculosis (TB) or
leprosy treatment, or preventively as a contact of another
index patient), (5) history of liver or renal disorders (eg,
jaundice), (6) leprosy disease, (7) signs and/or symptoms
of leprosy until negative diagnosis, (8) signs and/or symp-
toms of TB until negative diagnosis (patients having any
of the following symptoms are referred for full TB assess-
ment: cough for more than 2 weeks, night sweats, unex-
plained fever, weight loss) and (9) known allergy to
rifampicin.
Table 2 presents the study modalities in the different
countries. Leprosy services are integrated into primary
healthcare services in all LPEP countries, with passive
case detection as the core strategy of the routine leprosy
programmes combined with contact tracing in all coun-
tries except Tanzania (see online supplementary annex
2). Focal persons for diagnosis of leprosy vary from non-
clinician health professionals in Indonesia, Myanmar
and Nepal, to trained clinicians in India, Sri Lanka and
Tanzania. Notably, contact tracing, screening and diag-
nosis are all performed by different functions and
persons in Sri Lanka, demanding particularly robust
communication and information systems.
In most study areas the LPEP programme targets spe-
ciﬁc contact groups. Owing to high prevalence, its difﬁ-
cult access and the closed character of the community,
a blanket approach is applied in a village on the
Indonesian Selaru Island (Lingat) where all inhabitants
are screened and PEP is administered to all asymptom-
atic individuals.
Sample size calculation
To establish a decreasing trend in the NCDR of 10–15%
per year in every LPEP country, with sufﬁcient statistical
power (p=0.05), a logistic regression model suggests the
enrolment of between 175 (decrease of 15% in NCDR)
and 400 (decrease of 10% in NCDR) new index patients
per year.
Data collection and monitoring
The data collection and reporting solutions for LPEP
were developed or adapted by the technical partners in
close collaboration with the national leprosy pro-
grammes and the in-country ILEP partners. To ensure
the seamless integration of the LPEP programme into
the national leprosy control programmes, existing data
collection and reporting systems were assessed. The aim
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Table 2 LPEP modalities in the participating countries
Activities India Indonesia Myanmar Nepal Sri Lanka Tanzania
Routine contact
tracing in the
national programme
HH members and
neighbours
HH members and
neighbours
HH members HH members and
neighbours
not systematic none
Contact definition in
LPEP
HH members, neighbours
and class fellows
HH members and
neighbours
HH members and
neighbours
HH members and
neighbours
HH members HH members
Estimated number of
contacts per index
patient
20 50 20 30 5 5
Screening period for
LPEP
Retrospective contact
tracing starting in 2013
Contact tracing starting in
2015
Retrospective contact
tracing starting in
2014
Retrospective
contact tracing
starting in 2014
Retrospective
contact tracing
starting in 2015
Retrospective
contact tracing
starting in 2014
Responsible for
contact tracing
Accredited social health
activist, para medical
worker, multipurpose health
worker
Village midwife Midwives, PHS2 or
JLW; supported by
(Assistant) LI
Leprosy focal
person and female
CHV
PHI Trained VHW
Responsible for
contact screening
Para medical worker and
multipurpose health worker
Self-screening; Leprosy
health worker at PHC
and Village midwife
Midwives, PHS2 or
JLW; supported by
(Assistant) LI
Leprosy focal
person and female
CHV
MOH VHW
Responsible for
diagnosis
Doctor at PHC Leprosy health worker at
PHC
Midwives, PHS2 or
JLW; supported by
(Assistant) LI
Leprosy focal
person/doctor
Dermatologist Clinician
Responsible for
SDR administration
Para medical worker and
multipurpose health worker
Leprosy health worker at
PHC
Midwives, PHS2 or
JLW; supported by
(Assistant) LI
Leprosy focal
person and female
CHV
MOH VHW
Minimum Age for
SDR
2 2 2 2 6 6
Level of data entry At district level At district level At national level At district level At district level At district level
CHV, community health volunteer; DTLC, district TB and leprosy coordinator; HH, household; JLW, junior leprosy worker; LI, leprosy inspector; LPEP, leprosy post-exposure prophylaxis; MOH,
medical officer of health; PHC, primary health centre; PHS2, public health supervisor 2; PHI, public health inspector; PMW, para medical worker; VHW, voluntary health worker.
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was to use the available structures wherever feasible
and thereby to minimise duplication of data collection
efforts between national programmes and LPEP.
Supplementary LPEP forms were then developed to
capture the not-routinely collected data. The minimally
required LPEP indicators are listed in online
supplementary annex 1. Sociodemographic informa-
tion, leprosy classiﬁcation and disability grade, disease
history (mode of detection, start of treatment) and pre-
vious rifampicin use (apart from MDT) are recorded
for all index patients. For contacts, data collection cap-
tures sociodemographic characteristics, relationship to
the index patient, contact category (household, neigh-
bour, social), BCG vaccination scar, outcome of the
screening (signs of leprosy or TB) and SDR exclusion
criteria. In addition, referrals and adverse events (AEs)
following SDR PEP are documented (see Ethics
section).
A programme-speciﬁc database is offered to participat-
ing countries but any locally developed database that ﬁts
the programme requirements is also accepted. For
example in Sri Lanka, a locally developed MySQL data-
base is used. Data entry is carried out continuously,
either at national or district level; and database copies
are regularly shared with the technical and ILEP
partners for veriﬁcation and interim analyses. Feasibility
will be evaluated in terms of coverage (proportion
of contacts traced, screened and receiving PEP, if
eligible), required resources and coordination efforts.
Effectiveness will be measured as the impact of the
LPEP programme on the NCDR of the pilot areas.
In addition to the routine surveillance and pro-
gramme-speciﬁc monitoring of the national programme,
twice yearly monitoring visits are conducted by the tech-
nical and in-country ILEP partners to monitor protocol
adherence, resolve operational questions and evaluate
the quality of procedures and data. Data collection and
monitoring will be maintained for 3 years.
ETHICS
An expert meeting, involving both tuberculosis and
leprosy experts, focused on the potential risk of promot-
ing rifampicin resistance through the use of SDR in
leprosy control. It concluded that current evidence
suggests that the risk of emerging rifampicin resistance
in M. tuberculosis is minimal, and that the beneﬁt of
reducing the leprosy NCDR largely outweighs that risk.34
The national leprosy programmes submitted the
country-speciﬁc LPEP protocol and data collection
instruments for review and approval to the relevant
ethics committees. There was no need for ethical clear-
ance in Indonesia as the country has already integrated
the principle of PEP into its routine leprosy programme
in several districts. In each of the participating countries,
a designated national expert from the Ministry of Health
acts as the principal investigator for the LPEP
programme.
Informed consent is obtained from all index patients
and contacts, either written or verbally, depending on
local practices for comparable studies and as approved
by the ethical committee. It contains information on
possible side effects of SDR (ie, inﬂuenza-like syndromes
and discolouration of urine) and details of how a
leprosy expert can be contacted in case of AEs or other
concerns. AEs are reported following national pharma-
covigilance guidelines and using the LPEP AE Form,
while referred for proper follow-up.
DISCUSSION
The WHO global strategy for leprosy control 2011–2015
called for increased investments in operational research
to support the overall aims of the global leprosy control
programme, and to evaluate novel and promising inter-
ventions.10 11 Being an essential building block of
various disease control and outbreak containment pro-
grammes, contact tracing and chemoprophylaxis have
been identiﬁed as key factors to sustainably reduce the
number of new patients and move towards M. leprae
transmission interruption. The LPEP programme is
designed to answer key questions regarding the imple-
mentation of chemoprophylaxis for leprosy control and
to provide evidence for the feasibility and impact of
contact tracing and PEP on the NCDR across a range of
different health systems and levels of leprosy endemicity.
The LPEP programme is accompanied by ancillary
studies. The cost-effectiveness study aims to measure the
local costs associated with contact tracing and PEP and
compare those to the costs of routine case detection and
treatment. The acceptability and perception studies
focus on knowledge and understanding of leprosy in
communities where LPEP is implemented, on attitudes
and behaviour towards persons affected by leprosy, and
views of the proposed intervention among different
stakeholders.
In Brazil and Cambodia, similar approaches, comple-
menting the evidence from the LPEP programme, are
tested. In Brazil, the government-funded ‘PEP-Hans’
project explores the administration of chemoprophylaxis
and immunoprophylaxis (SDR and BCG), to about 20
contacts per index patient. PEP-Hans is implemented in
16 municipalities of Mato Grosso, Pernambuco and
Tocantins states, and covers index patients diagnosed
from 2015 to 2017. An estimated 850 index patients with
17 000 contacts will be included each year. The inclusion
and exclusion criteria for SDR and BCG are aligned
with the LPEP programme, as are the main variables for
impact evaluation. Chemoprophylaxis and immunopro-
phylaxis cannot be co-administered since there is a
minimum waiting time of 24 hours for BCG after SDR,
and of 30 days for SDR after BCG. In Cambodia, the
administration of SDR to household and neighbour con-
tacts is evaluated within the ‘Retrospective Active Case
Finding’ project started in 2011. Given the relatively low
number of new patients with leprosy diagnosed in this
6 Barth-Jaeggi T, et al. BMJ Open 2016;6:e013633. doi:10.1136/bmjopen-2016-013633
Open Access
group.bmj.com on November 18, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
country, the contacts of all patients diagnosed in an
operational district since 2011 are traced, screened and
managed in a single ‘drive’. This approach is repeated
until all 31 high-priority operational districts have been
covered. The project is implemented by a consortium
involving the National Leprosy Elimination Programme,
CIOMAL (International Committee of the Order of
Malta for Leprosy Relief) and the Novartis Foundation.
OUTLOOK
After 3 years of SDR administration to contacts of
patients with leprosy, the full impact and feasibility of
the intervention will start to emerge in 2019. Data will
be analysed at country level, and pooled analyses will be
conducted as far as differences in the epidemiology and
set-up of national leprosy programmes allow.
The LPEP programme will help to translate the exist-
ing evidence on SDR PEP for reducing the risk of devel-
oping leprosy among contacts of patients with leprosy
into routine action by providing solid data from a range
of settings and conditions, established by national
leprosy control programmes themselves. Participating
countries will be in a good position to fully integrate
contact tracing and SDR PEP into their national leprosy
control strategies and expand the activities to additional
areas in the country.
Dissemination of the results and lessons learnt from
the LPEP programme will be carried out through publi-
cation in open access journals, as well as through reports
and conference abstracts and presentations. The data
will provide crucial guidance for Ministries of Health of
all leprosy endemic countries interested in applying a
similar approach. The results of the LPEP programme
will also be of great value for global policymakers when
deciding on resource allocation for the interruption of
M. leprae transmission.
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